Published in Cancer Weekly, October 11th, 2005
"Luminal, basal-like, normal-like, and erbB2+ subgroups" have been identified and "shown to have different prognoses," added R. Rouzier and colleagues at the University of Texas M.D. Anderson Cancer Center. In a recent study, they sought to "determine if these different molecular subtypes of breast cancer also respond differently to preoperative chemotherapy."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.